UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000018024
Receipt number R000012277
Scientific Title Plasma levobipivacaine concentration after abdominal block
Date of disclosure of the study information 2015/06/22
Last modified on 2015/10/07 14:44:05

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Plasma levobipivacaine concentration after abdominal block

Acronym

Plasma levobipivacaine concentration after abdominal block

Scientific Title

Plasma levobipivacaine concentration after abdominal block

Scientific Title:Acronym

Plasma levobipivacaine concentration after abdominal block

Region

Japan


Condition

Condition

colon carcinoma

Classification by specialty

Gastrointestinal surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

Measurementof plasma levobupivacaine after abdominal block

Basic objectives2

Pharmacokinetics

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2


Developmental phase

Not applicable


Assessment

Primary outcomes

plasma concentration

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

over 20 years old and scheduled for mid-line incision surgery of laparoscopic colectomy were recruited at Gunma University Hospital.

Key exclusion criteria

1)patient who did not have the block
2)patient who had an allergy to local anesthetics
3)patient who refused to join the study
4)patient who was judged as inadequite

Target sample size

36


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Nakajima Kunie

Organization

Gunma University Hospital

Division name

Anesthesiology

Zip code


Address

3-39-15 Showa, Maebashi, Gunma, Japan

TEL

027-220-8454

Email

knkunie@yahoo.co.jp


Public contact

Name of contact person

1st name
Middle name
Last name Nakajima

Organization

Gunma University Hospital

Division name

Anesthesiology

Zip code


Address

3-39-15 Shouwa, Mebashi, Gunma, Japan

TEL

0272208454

Homepage URL


Email

knkunie@yahoo.co.jp


Sponsor or person

Institute

Gunma Univresity Hospital

Institute

Department

Personal name



Funding Source

Organization

Grant-in-Aid for Scientific Research

Organization

Division

Category of Funding Organization

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2015 Year 06 Month 22 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2013 Year 04 Month 15 Day

Date of IRB


Anticipated trial start date

2013 Year 04 Month 15 Day

Last follow-up date

2015 Year 12 Month 15 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

the use of 150mg of levobupivacaine for RSB and TAPB before the operations seems almost safety as long as watching carefully at least 45 minutes after the blocks for mid-line incision surgery of laparoscopic colectomy.


Management information

Registered date

2015 Year 06 Month 22 Day

Last modified on

2015 Year 10 Month 07 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000012277


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name